Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mundipharma International Limited

https://www.mundipharma.com

Latest From Mundipharma International Limited

First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns

Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.

Biosimilars Commercial

ASCO Preview: Multiple Chinese Biotechs Showcase NSCLC Assets

Chinese biotechs Biokin, Dizal, Junshi and Kelun Biotech are presenting four of the most closely-followed oral reports at ASCO on new clinical results for their candidates for non-small cell lung cancer.

China Clinical Trials

Opportunities Amid Crisis: Junshi, Allist Look To Expand Pipelines Through Alliances, M&A

Against the prevailing headwinds in the biotech sector, two Chinese firms are bucking the trend of pipeline reorganization by eyeing the potential acquisition of assets from external partners to expand into more modalities and therapeutic areas.

China M & A

Finance Watch: Kenvue, Acelyrin Launch Biggest Biopharma IPOs Of 2023

Public Company Edition: J&J’s consumer health spinout Kenvue grossed $3.8bn in its public market debut and Acelyrin raised $540m in an upsized IPO. Also, Seres accessed $250m in new debt for Vowst commercialization while follow-on offerings raised $325m for ImmunoGen and $240m for Morphic. 

Financing Growth
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Drug Delivery
      • Controlled Release
  • Other Names / Subsidiaries
    • Cinfa Biotech GmbH
    • Mundipharma Biologics S.L.
    • Mundipharma EDO GmbH
    • Napp Pharmaceuticals Ltd.
    • Tolmar Australia Pty. Ltd.
UsernamePublicRestriction

Register